PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd (Otsuka) and H. Lundbeck A/S (Lundbeck) published results from research demonstrating that an investigational ...

Data from Phase 3 Trial demonstrated improvement in time to relapse, the primary efficacy endpoint, for patients receiving once-monthly aripiprazole IM depot formulation compared to placebo Results ...

According to the National Institute on Minority Health and Health Disparities (NIMHD), less than half of all Americans who have a mental disorder get proper treatment, and less than 10% of patients ...

Credit: Thinkstock. Abilify Asimtufii is intended for dosing every 2 months via intramuscular injection in the gluteal muscle. The Food and Drug Administration (FDA) has approved Abilify Asimtufii ® ...

The NDA is supported by data from a phase 1/2 trial that compared the investigational aripiprazole 2-month, long-acting injectable to aripiprazole 1-month depot. The Food and Drug Administration (FDA) ...

Longer-acting formulas have made the treatment of schizophrenia more convenient and reliable for patients. Now, stepping to the plate with another long-acting treatment are Otsuka and Lundbeck. On ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a new drug application for a treatment for schizophrenia or bipolar I disorder. The injectable ...

Abilify (aripiprazole) is a prescription atypical (second-generation) antipsychotic that treats depression, schizophrenia, and bipolar disorder. It also treats irritability related to autism and ...

Please provide your email address to receive an email when new articles are posted on . The FDA has accepted a new drug application for aripiprazole, a 2-month, ready-to-use, long-acting injectable ...

Abilify Asimtufii, the bipolar I disorder treatment from Otsuka and Lundbeck, has entered the world of CGI animation as part of a multichannel direct-to-consumer (DTC) campaign. The two drugmakers ...